Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Koike Sanso to Market Infectious Medical Waste Disposal System
May 20, 2002
-
ARCHIVE Specialist System for Surgeons to Begin from June
May 13, 2002
-
ARCHIVE OTC NEWS IN BRIEF
May 13, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 13, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
May 13, 2002
-
ARCHIVE President-elect Kobori to Follow Handa's Policy: MPC
May 13, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
May 13, 2002
-
ARCHIVE SSP, Kirin Screen New LMW Compounds for Drug Discovery
May 13, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
May 13, 2002
-
ARCHIVE Sumitomo Agrees with GSK on Naratripan
May 13, 2002
-
ARCHIVE The South Africa Clinical Trial Mission
May 13, 2002
-
ARCHIVE Takeda Restructures Intellectual Property Department
May 13, 2002
-
ARCHIVE BULLETIN
May 13, 2002
-
ARCHIVE Loratadine Recommended to Be Approved as New Anti-allergic Drug
May 13, 2002
-
ARCHIVE Japanese, US, EU Patent Systems Need to Be Unified: Dr Fujino
May 13, 2002
-
ARCHIVE Abbott Aims at 20th Position in Japan: Mr Liepmann
May 13, 2002
-
ARCHIVE Debates on Healthcare Reform Start: Diet
May 13, 2002
-
ARCHIVE Wholesalers Should Take Firm Stance in Price Negotiations: FJPWA
May 13, 2002
-
ARCHIVE Original Makers to Take Tougher Stance against Patent Infringement
May 13, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
May 13, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…